Study guide

10.2 Cholinergic Agonists & Muscarinic/Nicotinic Antagonists

APMLE Part I Basic Sciences Podiatry

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Lower Extremity Osteology

1.1 APMLE Part I Exam Structure, Policies & Scoring 1.2 Foot Osteology: Tarsals, Metatarsals, Phalanges & Sesamoids 1.3 Leg & Ankle Osteology: Tibia, Fibula & The Ankle Mortise 1.4 Pelvis, Femur & Patella Osteology: Landmarks & Biomechanics

2 Chapter 2: Lower Extremity Arthrology & Ligaments

2.1 Foot Articulations: Subtalar, Midtarsal, Lisfranc & Digital Joints 2.2 Talocrural (Ankle) & Knee Joints: Ligaments & Kinematics 2.3 Hip Joint & Pelvic Articulations: Capsular Structures & Dynamics

3 Chapter 3: Lower Extremity Myology & Compartments

3.1 Anterior & Lateral Compartments of the Leg 3.2 Superficial & Deep Posterior Compartments of the Leg 3.3 Plantar Layers & Intrinsic Musculature of the Foot 3.4 Thigh & Gluteal Musculature: Attachments & Innervations

4 Chapter 4: Lower Extremity Neurovascular & Topographical Anatomy

4.1 Lumbar & Sacral Plexuses, Peripheral Nerves & Dermatomes 4.2 Arterial Network, Venous Drainage & Lymphatics 4.3 Tarsal Tunnel, Femoral Triangle & Topographical Spaces

5 Chapter 5: Microbiology: Bacteriology, Zoonoses & Laboratory Methods

5.1 Gram-Positive Cocci & Bacilli in Podiatric Infections 5.2 Gram-Negative Bacilli & Opportunistic Pathogens 5.3 Anaerobic Pathogens & Diabetic Foot Infections 5.4 Bacterial Structure, Virulence Factors & Sterilization 5.5 Mycobacteria, Spirochetes, Mycoplasma & Zoonotic Infections 5.6 Antimicrobial Resistance, Susceptibility Testing, Specimen Handling & Vaccines

6 Chapter 6: Mycology, Virology, Parasitology & Clinical Immunology

6.1 Mycology: Dermatophytes, Onychomycosis & Systemic Mycoses 6.2 Clinically Relevant Viruses & Parasitic Infections 6.3 Innate & Adaptive Immunity Mechanisms 6.4 Hypersensitivity Reactions, Immunodeficiencies & Autoimmunity 6.5 Transplant & Tumor Immunology and Immunodiagnostic Methods

7 Chapter 7: General & Cellular Pathology

7.1 Cellular Injury, Adaptations & Cell Death Mechanisms 7.2 Acute vs Chronic Inflammation & Tissue Repair 7.3 Hemodynamic Disorders, Thrombosis, Embolism & Shock 7.4 Neoplasia, Oncogenes, Tumor Suppressors & Cutaneous Tumors

8 Chapter 8: Systemic & Podiatric Pathology

8.1 Atherosclerosis, Peripheral Artery Disease & Diabetic Microangiopathy 8.2 Osteoarthritis, Inflammatory Arthritides & Bone Infections 8.3 Neuropathic Disorders, Charcot Neuroarthropathy & Dermatopathology 8.4 Laboratory Diagnostics, Synovial Fluid & Biopsy Interpretation

9 Chapter 9: Organ-System Pathology

9.1 Anemias, Hemoglobinopathies, Leukemias & Immune Disorders 9.2 Cardiac & Pulmonary Pathology 9.3 Renal, Urogenital & Reproductive Pathology 9.4 Gastrointestinal, Hepatobiliary & Endocrine Pathology

10 Chapter 10: General Pharmacology, Autonomic Drugs & Toxicology

10.1 Pharmacokinetics, ADME & Receptor Dynamics 10.2 Cholinergic Agonists & Muscarinic/Nicotinic Antagonists 10.3 Adrenergic Agonists, Sympatholytics & Clinical Applications 10.4 Cardiovascular Pharmacology in Podiatric Patients 10.5 Drug Interactions, Adverse Effects, Pharmacogenomics & Toxicology

11 Chapter 11: Antimicrobial & Podiatric Therapeutics

11.1 Antibacterial Classes, Mechanisms & Resistances 11.2 Antifungal, Antiviral & Antiparasitic Therapeutics 11.3 NSAIDs, Opioids, Corticosteroids & Anti-Gout Agents 11.4 Local & General Anesthetic Pharmacology

12 Chapter 12: Systemic Pharmacology

12.1 Anticonvulsants, Antidepressants, Psychotropics & Skeletal Muscle Relaxants 12.2 Insulin & Noninsulin Glycemic Agents 12.3 Respiratory & Gastrointestinal Agents 12.4 DMARDs, Biologics, Antineoplastics & Immunosuppressants 12.5 Hormone Therapy, Bisphosphonates, Antihistamines, Growth Factors & Complementary Agents

13 Chapter 13: General Anatomy: Systemic Gross Anatomy & Neuroanatomy

13.1 Cranial Nerves, Head & Neck Anatomy 13.2 Thoracic Wall, Tracheobronchial Tree, Lungs & Mediastinum 13.3 Abdominal Wall, GI Viscera, Pelvis & Retroperitoneum 13.4 Vertebral Column, Spinal Cord & Upper Extremity Overview 13.5 Neuroanatomy: CNS Organization, Somatosensory & Motor Pathways

14 Chapter 14: Histology, Integument, Embryology & Genetics

14.1 Microscopic Anatomy: Epithelia, Connective Tissue, Muscle & Nerve 14.2 Integumentary System: Dermis, Appendages, Nail Unit & Cutaneous Receptors 14.3 Embryogenesis, Limb Morphogenesis & Postnatal Development 14.4 Medical Genetics & Structural Alterations in Aging

15 Chapter 15: Cellular, Neuromuscular & Cardiovascular Physiology

15.1 Membrane Potential, Ion Channels & Transport Mechanisms 15.2 Action Potentials, Synaptic Transmission & Muscle Contraction 15.3 Cardiac Electrophysiology, ECG & Hemodynamics 15.4 Blood Pressure Regulation, Poiseuille Law & Capillary Dynamics

16 Chapter 16: Organ-System Physiology: Respiratory, Renal, Endocrine, GI & Blood

16.1 Pulmonary Mechanics, Gas Exchange & Acid-Base Regulation 16.2 Renal Filtration, Tubular Transport & Fluid/Acid-Base Balance 16.3 Endocrine Regulation, Reproductive Hormones, Calcium & Bone 16.4 Gastrointestinal & Hepatobiliary Physiology 16.5 Hematology: Erythropoiesis, Leukocytes, Platelets & Coagulation 16.6 Exercise Physiology, Thermoregulation & Bone Mechanobiology

17 Chapter 17: Biochemistry: Proteins, Enzymes, Carbohydrates & Signaling

17.1 Amino Acid Chemistry, Protein Structure & Enzyme Kinetics 17.2 Glycolysis, Gluconeogenesis, Glycogen Metabolism & TCA Cycle 17.3 Electron Transport Chain, ATP Synthesis & Metabolic Inborn Errors 17.4 Hormones, Receptors, Second Messengers & Signal Transduction

18 Chapter 18: Biochemistry: Lipids, Molecular Genetics, Blood Chemistry & Nutrition

18.1 Fatty Acid Oxidation, Ketogenesis, Cholesterol & Lipoproteins 18.2 Nucleotide Metabolism, DNA Replication, Transcription, Translation & Repair 18.3 Vitamins, Micronutrients & Inborn Errors of Metabolism 18.4 Blood Chemistry: Heme Metabolism, Hemoglobin & Plasma Proteins 18.5 Nutrition: Energy Balance, Glycemic Index, Fed-Fast Cycle & Free Radicals

10.2 Cholinergic Agonists & Muscarinic/Nicotinic Antagonists

Key Takeaways Explain This Topic AI

Acetylcholine (ACh) neurotransmission is terminated primarily by synaptic acetylcholinesterase (AChE) hydrolysis; vesicular release requires SNARE proteins, which are cleaved and inactivated by botulinum toxin.

Muscarinic receptors utilize distinct G-protein cascades: M1 and M3 couple to Gq (activating phospholipase C, increasing IP3/DAG, and elevating intracellular calcium), while M2 couples to Gi in cardiac nodal tissue (decreasing cAMP, slowing heart rate and AV conduction).

Direct muscarinic agonists (bethanechol, pilocarpine) stimulate smooth muscle and gland secretions, whereas indirect AChE inhibitors (neostigmine, pyridostigmine, donepezil) amplify endogenous acetylcholine signaling at both muscarinic and nicotinic synapses.

Organophosphate pesticide poisoning causes irreversible AChE phosphorylation and subsequent chemical 'aging', manifesting as cholinergic crisis (DUMBBELLS); therapy requires atropine for muscarinic blockade plus pralidoxime (2-PAM) prior to aging to reactivate the enzyme.

Neuromuscular blockers comprise depolarizing agents (succinylcholine: causes Phase I fasciculations followed by flaccid block; carries risks of malignant hyperthermia treatable with dantrolene and hyperkalemia) and non-depolarizing competitive antagonists (rocuronium, vecuronium, cisatracurium) reversible with neostigmine/glycopyrrolate or sugammadex.

Last updated: October 2026

10.2 Cholinergic Agonists & Muscarinic/Nicotinic Antagonists

Independent Study Guide Notice: Independent study guide by ExamFinch. This educational resource is developed independently by ExamFinch and is not sponsored, endorsed, or affiliated with the National Board of Podiatric Medical Examiners (NBPME) or Meazure Learning.

Neurochemical Transmission of Acetylcholine

Acetylcholine (ACh) is the primary neurotransmitter of the parasympathetic nervous system, all autonomic preganglionic fibers (both sympathetic and parasympathetic), somatic neuromuscular junctions, and sympathetic postganglionic fibers innervating eccrine sweat glands.

Biosynthesis, Packaging & Release

Synthesis: Choline is transported into presynaptic cholinergic nerve terminals via a high-affinity, sodium-dependent choline transporter (CHT1) (inhibited by hemicholinium). Intracellularly, the cytosolic enzyme Choline Acetyltransferase (ChAT) catalyzes the transfer of an acetyl group from Acetyl-CoA (derived from mitochondrial metabolism) to choline, yielding acetylcholine.

Vesicular Storage: ACh is pumped into synaptic storage vesicles by the Vesicular Acetylcholine Transporter (VAChT) , an antiporter driven by a proton gradient (inhibited experimentally by vesamicol).

Exocytosis & SNARE Proteins: Action potential arrival depolarizes the presynaptic terminal, triggering influx of extracellular calcium via voltage-gated N-type calcium channels. Calcium binds to synaptotagmin , triggering conformational assembly of the SNARE (Soluble N-ethylmaleimide-sensitive factor Attachment protein Receptor) complex :

Synaptobrevin (VAMP): Vesicle-associated membrane protein.

Syntaxin & SNAP-25: Target plasma membrane proteins.

The SNARE complex pulls the vesicle membrane into contact with the presynaptic terminal membrane, driving membrane fusion and pore opening to release ACh into the synaptic cleft.

Neurotoxin Disruption:

Botulinum Toxin ( Clostridium botulinum ): Cleaves specific SNARE proteins (SNAP-25 and synaptobrevin), permanently blocking ACh exocytosis at somatic neuromuscular junctions and autonomic synapses, producing flaccid paralysis.

Black Widow Spider Venom ( α \alpha α -Latrotoxin): Inserts into the presynaptic membrane, forming calcium-permeable pores that trigger massive, uncontrolled, explosive exocytosis of ACh, causing intense muscle cramping and spasms.

Termination: Unlike catecholamines (which rely primarily on presynaptic reuptake), ACh signaling is terminated exclusively by rapid enzymatic degradation. Acetylcholinesterase (AChE) anchored to the post-synaptic basement membrane hydrolyzes ACh into acetate and choline within microseconds. Choline is subsequently transported back into the presynaptic terminal to replenish transmitter stores.

Cholinergic Receptor Taxonomy & Signaling

Cholinergic receptors are classified into two structurally and pharmacologically distinct classes: G-protein-coupled Muscarinic receptors and ligand-gated ionotropic Nicotinic receptors . Cholinergic Receptors

  • │
  • ┌────────────────────────────┴───────────────────────────┐
  • Muscarinic (GPCRs) Nicotinic (Ion Channels)
  • │ │
  • ┌────────┴────────┐ ┌─────────┴─────────┐
  • Gq Gi Nm Nn
  • (M1, M3) (M2) (Neuromuscular) (Autonomic)
  • │ │ │ │
  • PLC → IP3/DAG ↓ Adenylyl Cyclase Motor Endplate Autonomic Ganglia
  • ↑ Intracellular ↓ cAMP Na+/K+ Influx Adrenal Medulla
  • Calcium SA/AV Node Inhibition Muscle Contraction Epi/NE Secretion
  • Muscarinic Receptors ( M 1 , M 2 , M 3 M_1, M_2, M_3 M 1 ​ , M 2 ​ , M 3 ​ )

Receptor Subtype G-Protein Coupling Signal Transduction Cascade Primary Anatomical Distribution Physiological Board-Tested Effects

M 1 M_1 M 1 ​ G q G_q G q ​ Phospholipase C (PLC) → ↑ I P 3 , D A G → ↑ C a 2 + \rightarrow \uparrow IP_3, DAG \rightarrow \uparrow Ca^{2+} →↑ I P 3 ​ , D A G →↑ C a 2 + , PKC activation CNS, enteric nervous system, gastric parietal cells Memory consolidation; stimulation of gastric acid secretion

M 2 M_2 M 2 ​ G i G_i G i ​ Inhibits adenylyl cyclase → ↓ c A M P \rightarrow \downarrow cAMP →↓ c A MP ; opens inward-rectifying K + K^+ K + channels ( I K , A C h I_{K,ACh} I K , A C h ​ ) Sinoatrial (SA) node, Atrioventricular (AV) node, atrial myocardium Negative chronotropy (decreased heart rate); negative dromotropy (slowed AV node conduction velocity); decreased atrial contractility

M 3 M_3 M 3 ​ G q G_q G q ​ Phospholipase C → ↑ I P 3 , D A G → ↑ intracellular C a 2 + \rightarrow \uparrow IP_3, DAG \rightarrow \uparrow \text{intracellular } Ca^{2+} →↑ I P 3 ​ , D A G →↑ intracellular C a 2 + Bronchial smooth muscle, bladder detrusor, ciliary muscle, pupillary sphincter, exocrine glands, vascular endothelium Bronchoconstriction; detrusor contraction (urination); miosis (sphincter pupillae); ciliary spasm (near vision); profuse salivation/lacrimation/sweating (sympathetic cholinergic); endothelial vasodilation via nitric oxide (NO)

Note

Vascular M 3 M_3 M 3 ​ and Endothelial Nitric Oxide Vasodilation: Blood vessels lack direct parasympathetic cholinergic innervation. However, vascular endothelial cells express un-innervated M 3 M_3 M 3 ​ muscarinic receptors . Binding of circulating muscarinic agonists stimulates G q → elevated endothelial C a 2 + → G_q \rightarrow \text{elevated endothelial } Ca^{2+} \rightarrow G q ​ → elevated endothelial C a 2 + → activation of Endothelial Nitric Oxide Synthase (eNOS) . Synthesized Nitric Oxide (NO) diffuses into adjacent vascular smooth muscle, activating soluble guanylyl cyclase to elevate cyclic GMP ( c G M P cGMP c GMP ) , leading to protein kinase G (PKG) activation, dephosphorylation of myosin light chains, and profound vasodilation and hypotension . If the vascular endothelium is damaged or denuded, direct M 3 M_3 M 3 ​ activation on underlying vascular smooth muscle triggers paradoxical vasoconstriction.

Nicotinic Receptors ( N m , N n N_m, N_n N m ​ , N n ​ )

Nicotinic receptors are pentameric, ligand-gated ion channels composed of five transmembrane glycoprotein subunits arranged symmetrically around a central aqueous ion pore:

N m N_m N m ​ (Muscle Type): Situated exclusively at the skeletal muscle motor endplate (composed of ( α 1 ) 2 β 1 γ δ (\alpha_1)_2\beta_1\gamma\delta ( α 1 ​ ) 2 ​ β 1 ​ γ δ or ( α 1 ) 2 β 1 ϵ δ (\alpha_1)_2\beta_1\epsilon\delta ( α 1 ​ ) 2 ​ β 1 ​ ϵδ ). Binding of two ACh molecules induces channel opening, driving rapid influx of extracellular N a + Na^+ N a + and minor efflux of K + K^+ K + . This generates an Endplate Potential (EPP) , depolarizing the sarcolemma to fire muscle action potentials and initiate excitation-contraction coupling.

N n N_n N n ​ (Neuronal Type): Located on postganglionic neurons in all autonomic ganglia (sympathetic and parasympathetic), within the adrenal medulla, and in the central nervous system (composed of α \alpha α and β \beta β subunit variations). Activation mediates ganglionic transmission and triggers catecholamine (epinephrine and norepinephrine) secretion directly into the bloodstream from chromaffin cells.

  • Cholinomimetic Agonists: Direct & Indirect
  • Direct Muscarinic Agonists

Drug Pharmacologic Profile Clinical Indications Adverse Effects / Contraindications

Bethanechol Quaternary ammonium carbamate; completely resistant to AChE; selective for muscarinic receptors with virtually no nicotinic activity. Postoperative non-obstructive urinary retention , neurogenic bladder atony, postoperative paralytic ileus. Abdominal cramps, diarrhea, diaphoresis, bronchospasm; contraindicated in mechanical bladder or bowel obstruction.

Pilocarpine Tertiary amine alkaloid; resistant to AChE; lipid-soluble, readily crosses biological membranes and cornea. Acute angle-closure glaucoma (topical drops induce rapid miosis and open trabecular meshwork); Sjögren syndrome and radiation-induced xerostomia. Profuse sweating, nausea, visual blurring/ciliary spasm; contraindicated in acute iritis.

Carbachol Mixed muscarinic and nicotinic agonist; resistant to AChE. Topical ocular administration to produce pupillary miosis during intraocular cataract surgery; refractory open-angle glaucoma. Systemic cholinergic effects if absorbed; limited systemic use due to high nicotinic potency.

Methacholine Synthetic choline ester; metabolized slowly by AChE; inhaled aerosol. Bronchial challenge test to diagnose bronchial hyperreactivity in patients with suspected asthma showing normal baseline spirometry. Severe acute bronchospasm; must be administered in controlled pulmonary lab with rescue albuterol available.

Indirect-Acting Agonists (Acetylcholinesterase Inhibitors)

AChE inhibitors prevent the breakdown of endogenous ACh, thereby elevating synaptic ACh concentrations and amplifying stimulation at both muscarinic ( M 1 − M 3 M_1 - M_3 M 1 ​ − M 3 ​ ) and nicotinic ( N m , N n N_m, N_n N m ​ , N n ​ ) receptors.

Agent Chemical Class & BBB Penetration Duration & Mechanism Clinical Podiatric & Medical Use

Neostigmine Quaternary amine (polar, charged); DOES NOT cross Blood-Brain Barrier (BBB) Intermediate (2–4 hrs); carbamylates active serine of AChE Postoperative reversal of non-depolarizing neuromuscular blockade ; postoperative ileus and urinary retention; symptomatic Myasthenia Gravis.

Pyridostigmine Quaternary amine ; does NOT cross BBB Long-acting (4–6 hrs); reversible carbamylate inhibitor First-line oral maintenance pharmacotherapy for Myasthenia Gravis ( "Pyri-STIG-mine STAYS on the job" ).

Edrophonium Quaternary amine ; does NOT cross BBB Ultra-short acting (5–10 min); reversible electrostatic binding (non-covalent) Historically utilized in the Tensilon test to differentiate Myasthenic crisis (improves with drug) from Cholinergic crisis (worsens with drug).

Physostigmine Tertiary amine (non-polar, lipophilic); CROSSES Blood-Brain Barrier into CNS Intermediate (1–2 hrs); carbamylate inhibitor Antidote of choice for Anticholinergic Toxidrome (e.g., severe central and peripheral atropine, diphenhydramine, or scopolamine overdose).

Donepezil, Rivastigmine, Galantamine Lipophilic compounds; easily cross BBB into central synapses Reversible, CNS-selective AChE inhibitors First-line symptomatic treatment for mild-to-moderate Alzheimer disease ; enhances central cognitive cholinergic transmission.

  • Organophosphate Poisoning & The Cholinergic Crisis
  • Organophosphate Toxicology & Chemical "Aging"

Organophosphates (e.g., parathion, malathion, echothiophate, and chemical nerve agents including sarin, soman, and tabun) are lipid-soluble compounds that bind covalently to the serine hydroxyl group in the catalytic triad of acetylcholinesterase, forming an exceptionally stable, irreversible phosphorylated enzyme complex .

Chemical Aging: Over subsequent minutes to hours, the phosphorylated enzyme undergoes a spontaneous dealkylation reaction termed "aging" . Once aging occurs, the chemical bond is permanently cleaved and stabilized, rendering the enzyme completely refractory to chemical reactivation. Pharmacotherapy must be initiated rapidly prior to aging.

Clinical Manifestations: The DUMBBELLS Toxidrome

Accumulation of acetylcholine at all cholinergic synapses produces widespread crisis:

DUMBBELLS Mnemonic for Muscarinic Hyperstimulation: \textbf{DUMBBELLS Mnemonic for Muscarinic Hyperstimulation:} DUMBBELLS Mnemonic for Muscarinic Hyperstimulation:

  • D: Diarrhea and abdominal cramping
  • U: Urination (detrusor contraction, sphincter relaxation)
  • M: Miosis (pinpoint pupils via pupillary sphincter contraction)

B: Bradycardia (M2 SA nodal inhibition) & Bronchorrhea / Bronchospasm (M3 airway flooding and constriction — primary cause of mortality )

  • E: Emesis
  • L: Lacrimation
  • L: Lethargy and central seizures
  • S: Salivation and Sweating (sympathetic cholinergic)

In addition to muscarinic signs, hyperstimulation at Nicotinic ( N m N_m N m ​ ) receptors produces muscle fasciculations, cramping, and subsequent depolarization neuromuscular blockade leading to flaccid diaphragmatic paralysis and respiratory arrest .

Definitive Antidote Protocol

Important

Dual Pharmacotherapy for Organophosphate Poisoning:

Atropine: Competitive muscarinic receptor antagonist. Readily crosses the BBB. Atropine reverses all lethal muscarinic manifestations—specifically drying up life-threatening bronchorrhea, relieving bronchospasm, and reversing profound bradycardia . Titrated aggressively until bronchial secretions clear. Atropine has zero effect on nicotinic receptors and does not treat skeletal muscle weakness or respiratory muscle paralysis!

Pralidoxime (2-PAM): Acetylcholinesterase reactivator. Possesses a high-affinity oxime group that binds the organophosphate-inactivated AChE and attacks the phosphorus atom, hydrolyzing the covalent phosphate-enzyme bond and regenerating functional acetylcholinesterase. Pralidoxime regenerates neuromuscular junction ( N m N_m N m ​ ) transmission, reversing muscle weakness and paralysis. Must be administered before chemical aging occurs. Because 2-PAM is a quaternary amine, it does not penetrate the BBB and acts only at peripheral synapses.

Loading diagram... Organophosphate Intoxication, Aging, and Dual Antidote Action

Muscarinic Antagonists (Anticholinergics)

Muscarinic receptor antagonists competitively inhibit acetylcholine binding at postganglionic parasympathetic neuroeffector junctions.

High-Yield Antimuscarinic Drugs

Atropine: Prototypic non-selective competitive muscarinic blocker; tertiary amine crossing the BBB. First-line pharmacotherapy for symptomatic sinus bradycardia, organophosphate intoxication, and intraoperative antisialagogue to reduce airway secretions.

Scopolamine: Tertiary amine with pronounced CNS penetration; acts on vestibular muscarinic pathways to prevent and treat motion sickness (transdermal patch) and postoperative nausea.

Ipratropium & Tiotropium: Inhaled quaternary ammonium antimuscarinics (minimal systemic absorption); block bronchial M 3 M_3 M 3 ​ receptors to promote bronchodilation and reduce mucous secretions. First-line therapy for Chronic Obstructive Pulmonary Disease (COPD) and adjunctive in acute asthma.

Oxybutynin, Tolterodine, Solifenacin: Antimuscarinics with selectivity for bladder M 3 M_3 M 3 ​ receptors; relax the detrusor muscle to treat urgency urinary incontinence and overactive bladder .

Glycopyrrolate: Quaternary amine antimuscarinic; does not cross the blood-brain barrier . Used perioperatively to reduce salivary and respiratory secretions and co-administered with neostigmine during neuromuscular block reversal to prevent muscarinic bradycardia without inducing central anticholinergic delirium.

Benztropine & Trihexyphenidyl: Centrally active tertiary antimuscarinics; cross the BBB to restore the dopaminergic-cholinergic balance in the striatum. Used in Parkinson disease and for the prevention and reversal of acute drug-induced extrapyramidal symptoms (acute dystonia) caused by antipsychotics.

Anticholinergic Toxidrome

Overdose or adverse accumulation of antimuscarinic agents (including atropine, tricyclic antidepressants, first-generation antihistamines, and belladonna alkaloids) triggers a classic clinical toxidrome:

Anticholinergic Toxidrome Classic Mnemonic: \textbf{Anticholinergic Toxidrome Classic Mnemonic:} Anticholinergic Toxidrome Classic Mnemonic:

"Blind as a bat": Mydriasis (pupillary dilation via unopposed sympathetic α 1 \alpha_1 α 1 ​ ) and cycloplegia (ciliary muscle paralysis, loss of near accommodation).

"Mad as a hatter": Central muscarinic blockade causing confusion, delirium, acute agitation, visual hallucinations, and encephalopathy.

"Red as a beet": Cutaneous vasodilation producing diffuse facial and upper body flushing (compensatory cutaneous shunting to dissipate heat).

"Hot as a hare": Severe hyperthermia resulting from complete shutdown of eccrine sweat glands (loss of sympathetic cholinergic M 3 M_3 M 3 ​ diaphoresis).

"Dry as a bone": Total xerostomia, cracked lips, and anhidrosis (dry skin).

"Full as a flask": Severe urinary retention (detrusor relaxation and internal sphincter closure) and severe constipation / paralytic ileus.

Cardiovascular: Sinus tachycardia due to blockade of vagal M 2 M_2 M 2 ​ receptors on the SA node.

Neuromuscular Blocking Agents (NMBs)

Neuromuscular blocking drugs are administered during surgical induction to achieve skeletal muscle relaxation and facilitate endotracheal intubation. They act specifically at the N m N_m N m ​ nicotinic receptors of the skeletal motor endplate.

Depolarizing NMB: Succinylcholine

Mechanism of Action: Succinylcholine is composed of two conjoined acetylcholine molecules. It binds to the N m N_m N m ​ nicotinic receptor and stimulates it continuously, acting as a non-metabolized agonist:

Phase I Block (Depolarizing Phase): Produces initial, disorganized motor unit depolarizations visible clinically as muscle fasciculations . Because succinylcholine is not degraded by synaptic AChE, the motor endplate remains persistently depolarized ( > − 55 mV > -55\text{ mV} > − 55 mV ). The perijunctional voltage-gated sodium channels enter a prolonged, locked inactivated state , preventing propagation of further action potentials and resulting in flaccid paralysis. Phase I block is augmented, not reversed, by acetylcholinesterase inhibitors like neostigmine!

Phase II Block (Desensitization Phase): With prolonged exposure or continuous infusion, the endplate membrane eventually repolarizes, but the nicotinic receptors become desensitized and refractory to acetylcholine. The characteristics of Phase II block resemble those of a non-depolarizing blockade and can theoretically be reversed by AChE inhibitors.

Metabolism: Succinylcholine is cleared extremely rapidly from systemic circulation by Plasma Pseudocholinesterase (Butyrylcholinesterase) , yielding a brief clinical duration of 5 − 10 minutes 5 - 10\text{ minutes} 5 − 10 minutes .

Caution

Atypical Pseudocholinesterase & Prolonged Apnea: Patients with inherited genetic variants in the pseudocholinesterase gene ( BCHE ) cannot metabolize succinylcholine at normal rates. Following standard intubating doses, these individuals experience prolonged neuromuscular paralysis and apnea lasting several hours , requiring sustained mechanical ventilation until the drug slowly clears through spontaneous diffusion and renal excretion.

Adverse Effects of Succinylcholine:

Hyperkalemia: Persistent open-state N m N_m N m ​ channels allow sustained intracellular K + K^+ K + efflux into systemic circulation, normally raising serum potassium by 0.5 mEq/L 0.5\text{ mEq/L} 0.5 mEq/L . However, in patients with denervation injuries (spinal cord transection, stroke), extensive burn injuries, severe crush trauma, or muscular dystrophies , widespread upregulation of extrajunctional nicotinic receptors occurs across the entire muscle sarcolemma. Administration of succinylcholine in these patients triggers massive, catastrophic hyperkalemia leading to ventricular fibrillation and cardiac arrest .

Increased Intraocular and Intragastric Pressure: Fasciculations can transiently elevate pressure, risking extrusion of ocular contents in open-globe trauma.

Malignant Hyperthermia

Malignant Hyperthermia (MH) is a life-threatening, pharmacogenetic hypermetabolic crisis triggered when susceptible individuals are exposed to succinylcholine or volatile halogenated inhalational anesthetics (e.g., halothane, isoflurane, sevoflurane, desflurane).

Pathophysiology: Caused by an autosomal dominant mutation in the Ryanodine Receptor Gene ( RYR1 ) (or less commonly CACNA1S ), which encodes the calcium release channel of the sarcoplasmic reticulum in skeletal muscle. Triggering agents cause uncontrolled, sustained, massive efflux of stored calcium from the sarcoplasmic reticulum into the myoplasm. Unchecked calcium activates myosin ATPase, stimulating continuous excitation-contraction coupling, sustained muscle rigidity, and catastrophic depletion of cellular ATP.

Clinical Presentation: Earliest signs include unexplained tachycardia, acute tachypnea, and rapidly rising end-tidal C O 2 CO_2 C O 2 ​ ( E T C O 2 ETCO_2 ETC O 2 ​ ) refractory to hyperventilation. Patients develop masseter muscle spasm / rigidity , generalized skeletal muscle rigidity, severe metabolic and respiratory acidosis, rhabdomyolysis (hyperkalemia, hyperphosphatemia, myoglobinuria risking acute renal failure), and dramatic late hyperthermia ( > 40 ° C / 104 ° F > 40°\text{C} / 104°\text{F} > 40° C /104° F ) .

Treatment:

Immediately discontinue all volatile anesthetics and succinylcholine; hyperventilate with 100 % O 2 100\% O_2 100% O 2 ​ .

Administer intravenous Dantrolene ( 2.5 mg/kg 2.5\text{ mg/kg} 2.5 mg/kg IV push, repeated as necessary). Mechanism of Dantrolene: Directly binds to the ryanodine receptor (RYR1) on the sarcoplasmic reticulum, blocking channel opening and preventing further calcium efflux into the myoplasm, halting the hypermetabolic cascade.

Active external and internal cooling, intravenous sodium bicarbonate for severe acidosis, and aggressive diuresis with IV fluids to protect against myoglobinuric acute tubular necrosis.

Non-Depolarizing NMBs & Pharmacologic Reversal

Non-depolarizing agents act as competitive antagonists at the N m N_m N m ​ receptor. They prevent acetylcholine from binding, preventing depolarization of the motor endplate. Unlike succinylcholine, they cause no muscle fasciculations .

Non-Depolarizing Agent Metabolism & Elimination Clinical Characteristics

Rocuronium Hepatic uptake and biliary excretion ( > 70 % > 70\% > 70% ); renal excretion ( 30 % 30\% 30% ) Intermediate duration (30–60 min); rapid onset makes it the preferred alternative to succinylcholine for rapid sequence intubation (RSI).

Vecuronium Hepatic metabolism and biliary excretion; renal excretion Intermediate duration; excellent cardiovascular stability with minimal histamine release.

Cisatracurium Hofmann Elimination: Spontaneous, non-enzymatic chemical breakdown in plasma at physiologic body temperature and pH. Intermediate duration; drug of choice in patients with severe renal or hepatic failure , as clearance is completely organ-independent.

Pancuronium Renal elimination ( 80 % 80\% 80% ) Long duration ( > 90 min > 90\text{ min} > 90 min ); possesses vagolytic activity, inducing moderate sinus tachycardia.

Reversal of Non-Depolarizing Blockade

At the conclusion of surgical procedures, non-depolarizing blockade must be actively reversed:

Acetylcholinesterase Inhibitors (Neostigmine): Inhibits AChE, raising synaptic ACh levels to competitively displace the non-depolarizing blocker from the N m N_m N m ​ receptor. To prevent neostigmine from stimulating muscarinic receptors and inducing severe bradycardia, bronchospasm, and salivation, it must always be co-administered with a muscarinic antagonist :

Neostigmine + Glycopyrrolate (matched onset profiles; glycopyrrolate does not cross BBB, preventing central delirium).

Sugammadex: A modified γ \gamma γ -cyclodextrin macrocycle that reverses rocuronium and vecuronium . Sugammadex does not alter ACh concentrations; instead, it acts as a chemical chelator that encapsulates rocuronium molecules in plasma in a 1 : 1 1:1 1 : 1 stoichiometric complex, rendering them inactive and driving diffusion away from neuromuscular junctions. Provides ultra-rapid reversal without cholinergic or anticholinergic adverse effects.